硫酸镁治疗可改善蛛网膜下腔出血患者的预后：一项荟萃分析研究。
Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study.
机构信息
Department of Neurology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
出版信息
Transl Stroke Res. 2010 Jun;1(2):108-12. doi: 10.1007/s12975-010-0022-8.
OBJECTIVE
To elucidate the role of magnesium sulfate in patients with subarachnoid hemorrhagic (SAH) brain injury
METHOD
Studies for the meta-analysis were identified from PubMed (1966 to 2009), Embase (1980 to 2009), and two Chinese journals (1989 to 2009). Paper selection was based on randomized controlled trials comparing magnesium sulfate to placebo treatment in patients with SAH. Two independent review authors extracted the data and assessed trial quality. Meta-analysis was performed using the Cochrane Review Manger software.
RESULTS
Five trials involving 482 patients were included in the review. Magnesium sulfate reduced the risk of poor outcome and reduced the occurrence of delayed cerebral ischemia. In the treatment groups, relative risk for poor outcome was 0.73 (CI 0.57-0.93) and 0.66 (CI 0.47-0.92) for delayed cerebral ischemia. Case fatality assessment at three to six months did not show statistically significant data (RR 0.88; CI 0.61-1.29).
CONCLUSION
Magnesium sulfate appears to be an effective treatment option in the management of SAH. Further clinical trials are needed before magnesium sulfate can become a routine treatment for SAH.
目的
阐明硫酸镁在蛛网膜下腔出血（SAH）脑损伤患者中的作用。
方法
从 PubMed（1966 年至 2009 年）、Embase（1980 年至 2009 年）和两个中文期刊（1989 年至 2009 年）中确定了用于荟萃分析的研究。基于硫酸镁与安慰剂治疗 SAH 患者的随机对照试验来选择论文。两位独立的综述作者提取数据并评估试验质量。使用 Cochrane Review Manger 软件进行荟萃分析。
结果
综述共纳入了 5 项涉及 482 例患者的试验。硫酸镁降低了不良结局的风险并减少了迟发性脑缺血的发生。在治疗组中，不良结局的相对风险为 0.73（95%CI 0.57-0.93）和 0.66（95%CI 0.47-0.92），迟发性脑缺血的发生风险。3 至 6 个月时的病死率评估未显示出统计学意义的数据（RR 0.88；95%CI 0.61-1.29）。
结论
硫酸镁似乎是治疗 SAH 的有效治疗选择。在硫酸镁成为 SAH 的常规治疗方法之前，还需要进行更多的临床试验。
Zotero 插件